| Author |
No. of Patients |
Induction Therapy |
Maintenance Therapy |
Acute Rejection at 1 year |
Patient Survival |
Graft Survival |
Infections |
Other |
| Brennan et al. [7] |
141
137 |
rATG
Basiliximab |
Csa
MMF
Prednisone |
rATG: 15.6%
Basiliximab:
25.5%
P=0.02 |
At 1 year:
rATG: 95.7%
Basiliximab: 95.6%
No significant difference |
At 1 year:
rATG: 90.8%
Basiliximab: 89.8%
No significant difference |
rATG: 85.8%
Basiliximab: 75.2%
P=0.03 |
No difference in incidence of cancer between the groups |
| Cantarovich et al. [57] |
99 CSWD
98 CCS |
rATG
rATG |
Csa
MMF
+/- prednisone |
At 1 year:
CSWD: 17.3%
CCS: 7.1%
P=0.031 |
At 1 year:
CSWD: 97.1%
CCS: 99.0%
No significant difference |
At 1 year:
CSWD: 94.9%
CCS: 93.2%
No significant difference |
At 1 year:
CSWD: 67.3%
CCS: 72.8%
No significant difference |
The CCS group had a trend towards a higher incidence of malignancy at 1 year (P=0.059). |
| Cianco et al. [59] |
100
100 |
rATG/DAC
rATG/C1H |
FK
EC-MPS |
rATG/DAC: 11%
rATG/C1H: 9%
No significant difference |
At 4 years:
rATG/DAC: 96%
rATG/C1H: 92%
No significant difference |
At 4 years:
rATG/DAC: 91%
rATG/C1H: 83%
No significant difference |
At 1 year:
rATG/DAC: 22%
rATG/C1H: 21%
No significant difference |
No cases of PTLD occurred in either group |
| Hanaway et al. [51] |
251:
70 high risk 164 low risk
69
171 |
C1H
(high and low risk patients)
rATG (high risk patients only)
Basiliximab (low risk patients only) |
FK
MMF
Early steroid withdrawal |
Low risk patients:
C1H vs. basiliximab
(3 vs. 20, P<0.001)
High risk patients:
C1H vs. rATG
(11 vs. 13, P=0.53) |
At 3 years:
C1H 96%
Basiliximab 98%
rATG 91%
No significant difference |
At 3 years:
C1H 95%
Basiliximab 94%
rATG 91%
No significant difference |
Serious Events at 3 years
Low risk (P=0.02): C1H 35%
Basiliximab 22
High risk (P=0.009):
C1H 60%
rATG 80% |
Incidence of cancer was significantly higher in the C1H group compared to rATG or basiliximab (P=0.03) |
| Lebranchu et al. [33] |
50
50 |
rATG
Basiliximab |
Csa
MMF
Prednisone (withdrawn at 6 months) |
rATG: 8%
Basiliximab: 10%
No significant difference |
At 1 year:
rATG: 100%
Basiliximab: 98%
No significant difference |
At 1 year:
rATG: 96%
Basiliximab: 94%
No significant difference |
At 1 year:
rATG: 86.0%
Basiliximab: 64.7%
No significant difference |
No cases of cancer occurred in either group |
| Mourad et al. [35] |
53
52 |
rATG
Basiliximab |
Csa
MMF
Prednisone |
rATG: 9.4%
Basiliximab: 9.6%
No significant difference |
At 1 year:
rATG: 98.1%
Basiliximab: 98.1%
No significant difference |
At 1 year:
rATG: 96.2%
Basiliximab: 94.2%
No significant difference |
At 1 year:
rATG: 53.0%
Basiliximab: 42.3%
No significant difference |
No cases of PTLD occurred in either group |
| Woodle et al. [37] |
CSWD group
(n=191)
CCS group
(n=195)
|
rATG
125 CSWD
136 CCS
IL-2RA
66 CSWD
59 CCS
|
FK
MMF
+/- prednisone |
CSWD:
rATG: 14.4%
Basiliximab: 24.2%
P=0.09
At 5 years:
CSWD: 17.8%
CCS: 10.8%
P=0.058 |
At 5 years:
CSWD: 94.2%
CCS: 93.3% |
At 5 years:
CSWD: 94.2%
CCS: 96.4% |
CSWD: 39.3%
CCS: 44.1%
No significant difference |
No difference in incidence of cancer between the CSWD and CCS groups |
